Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
JAMA · 15.08.2023 · 330 (7) · 650
DOI: 10.1001/jama.2023.13872 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 15.08.2023. Verfasst von Rasha Alhiary und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Drug Approval, Drugs, Generic, Hypoglycemic Agents. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Importance Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive.
Objective
To analyze how manufacturers of brand-name GLP-1 receptor agonists have used the patent and regulatory systems to extend periods of market exclusivity. Evidence Review The annual US Food and Drug Administration’s (FDA) Approved Drug Products With Therapeutic Equivalence Evaluations was used to identify GLP-1 receptor agonists approved from 2005 to 2021 and to record patents and nonpatent statutory exclusivities listed for each product. Google Patents was used to extract additional data on patents, including whether each was obtained on the delivery device or another aspect of the product. The primary outcome was the duration of expected protection from generic competition, defined as the time elapsed from FDA approval until expiration of the last-to-expire patent or regulatory exclusivity.
Findings
On the 10 GLP-1 receptor agonists included in the cohort, drug manufacturers listed with the FDA a median of 19.5 patents (IQR, 9.0-25.8) per product, including a median of 17 patents (IQR, 8.3-22.8) filed before FDA approval and 1.5 (IQR, 0-2.8) filed after FDA approval. Fifty-four percent of all patents listed on GLP-1 receptor agonists were on the delivery devices rather than active ingredients. Manufacturers augmented patent protection with a median of 2 regulatory exclusivities (IQR, 0-3) obtained at approval and 1 (IQR, 0.3-4.3) added after approval. The median total duration of expected protection after FDA approval, when accounting for both preapproval and postapproval patents and regulatory exclusivities, was 18.3 years (IQR, 16.0-19.4). No generic firm has successfully challenged patents on GLP-1 receptor agonists to gain FDA approval. Conclusions and Relevance Patent and regulatory reform is needed to ensure timely generic entry of GLP-1 receptor agonists to the market.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- West Virginia University College of Law, Morgantown.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Alhiary, R., Kesselheim, A. S., Gabriele, S., Beall, R. F., Tu, S. S., & Feldman, W. B. (2023). Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA, 330(7), 650. https://doi.org/10.1001/jama.2023.13872
Vancouver
Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA. 2023;330(7):650. doi:10.1001/jama.2023.13872
BibTeX
@article{Alhiary2023,
author = {Alhiary, Rasha and Kesselheim, Aaron S and Gabriele, Sarah and Beall, Reed F and Tu, S Sean and Feldman, William B},
title = {Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists},
journal = {JAMA},
year = {2023},
volume = {330},
number = {7},
pages = {650},
doi = {10.1001/jama.2023.13872}
}
EUVIMED